Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-749) for the Once-Monthly Treatment of Schizophrenia in Adults
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-749) for the Once-Monthly Treatment of Schizophrenia in Adults
📈 **POSITIVE** • Medium confidence analysis (77%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical